Ohr Pharmaceuticals Rises on Wet-AMD Treatment News- More to come? Print E-mail
By Staff and Wire Reports   
Wednesday, 22 June 2011 02:59
OhrShares of Ohr Pharmaceutical, Inc. (OTCBB:OHRP) rose 23.81% to 0.52 (+0.10) on Tuesday after our premium subscriber only analysis of news involving the company's reformulation of Squalamine, its Wet Age-related Macular Degeneration (“Wet-AMD”) program from an intravenous infusion (“IV”) to a topical eye drop.

Ohr's Topical Treatment of Wet-AMD Offers Several Advantages Over Current Standard-of-Care

Wet-AMD is a medical condition which usually affects older adults and generally results in a loss of vision. The wet form (Wet-AMD) accounts for approximately 15 percent of all AMD, yet is responsible for 90 percent of severe vision loss associated with AMD. According to the National Eye Institute (NEI), the prevalence of Wet-AMD among adults 40 years or older in the U.S. alone is estimated at 1.75 million people.    

Squalamine is a small molecule anti-angiogenic with a novel intracellular mechanism of action. The previous IV formulation had been awarded fast track status and a Special Protocol Assessment (“SPA”) by the FDA for a Phase III registration study in patients with Wet-AMD.

What does this mean for OHR?

This is not just the most important news in OHR’s short history, but may be the most significant event to date in Wet-AMD treatment.

"The Squalamine eye drop program has the potential to create a monumental shift in the way patients are treated for Wet-AMD," commented Dr. Shalom Z. Hirschman, M.D., Ohr's Chief Scientific Advisor.

The current standard of care for Wet-AMD is Lucentis, a $1.5B drug in annual sales that is delivered via intravitreal injection directly into the eye. If you or a loved one had the Wet-AMD condition, would you rather have monthly intravitreal injections, or use a simple eye drop? It’s a no-brainer.

In previous trials, Squalamine demonstrated a lower side effect profile, high efficacy, and an ability to also treat the fellow eye. Management will clearly move forward with its clinical program for the reformulated Squalamine. If results from the next phase of the clinical program are similar to previous trials, we believe that OHR is well-positioned to not just receive an FDA approval, but potentially emerge as the new standard of care for Wet-AMD treatment. This event should also put OHR firmly on big pharma’s radar screen as well.

Goldman Small Cap Research has recommended the purchase on the heels of this news and reiterated their $2.00 price target.

In addition to Goldman's recommendation, BioMedReports readers are advised to watchlist this stock as we are hearing more chatter regarding even more positive developments on the horizon (2-4 weeks?) for Ohr Pharmaceutical.


"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus